Tumor diagnosis preceding Parkinson's disease: A case–control study

Authors

  • Marco D'Amelio MD,

    1. Dipartimento di Neurologia, Ofthamologia, Otorinolaringoiatria, e Psichiatria, Università degli Studi di Palermo, Palermo, Italy
    Search for more papers by this author
  • Paolo Ragonese MD,

    1. Dipartimento di Neurologia, Ofthamologia, Otorinolaringoiatria, e Psichiatria, Università degli Studi di Palermo, Palermo, Italy
    Search for more papers by this author
  • Letterio Morgante MD,

    1. Dipartimento di Neurologia, Università degli Studi di Messina, Messina, Italy
    Search for more papers by this author
  • Antonio Epifanio MD,

    1. Dipartimento di Neurologia, Università degli Studi di Messina, Messina, Italy
    Search for more papers by this author
  • Graziella Callari MD,

    1. Dipartimento di Neurologia, Ofthamologia, Otorinolaringoiatria, e Psichiatria, Università degli Studi di Palermo, Palermo, Italy
    Search for more papers by this author
  • Giuseppe Salemi MD,

    1. Dipartimento di Neurologia, Ofthamologia, Otorinolaringoiatria, e Psichiatria, Università degli Studi di Palermo, Palermo, Italy
    Search for more papers by this author
  • Giovanni Savettieri MD

    Corresponding author
    1. Dipartimento di Neurologia, Ofthamologia, Otorinolaringoiatria, e Psichiatria, Università degli Studi di Palermo, Palermo, Italy
    • Dipartmento di Neurologia, ofthamologia, otolaringoiatria, e Psichiatria, Università degli Studi di Palermo, via Gaetano La Loggia 1, 90129 Palermo, Italy
    Search for more papers by this author

Abstract

Lower cancer risk in Parkinson's disease (PD) patients compared to the general population has been reported. However, most of the studies were based on death certificates. We designed a case–control study to estimate the association of tumor preceding PD onset and PD. PD patients were matched by age and gender to PD-free individuals, randomly selected from the municipalities of residence of cases. Occurrence of tumors preceding PD onset was assessed through a structured questionnaire. Neoplasms were categorized as benign, malignant, or of uncertain classification, and endocrine-related or not. Odds ratios (OR) were calculated using conditional logistic regression and adjusted for tumor categories and risk factors. We included 222 PD patients. Frequency of cancer was 6.8% for cases, 12.6% for controls. PD patients had a decreased risk for neoplasms (adjusted OR, 0.4; 95% confidence interval [CI], 0.2–0.7). Risk was reduced only for women (adjusted OR, 0.3; 95% CI, 0.1–0.7). PD patients had a decreased risk both for malignant (adjusted OR, 0.6; 95% CI, 0.1–2.5) and nonmalignant neoplasms (adjusted OR, 0.3; 95% CI, 0.1–0.7). Still, risk was decreased for endocrine-related tumors (adjusted OR, 0.3; 95% CI, 0.1–0.9) and non–endocrine-related tumors (adjusted OR, 0.4; 95% CI, 0.1–0.9). Our study confirms the inverse association between PD and neoplasms reported in previous epidemiologic studies. © 2004 Movement Disorder Society

Ancillary